Prothena Corporation PLC (NASDAQ:PRTA) Director Christopher S. Henney sold 900 shares of Prothena Corporation PLC stock in a transaction on Thursday, September 28th. The shares were sold at an average price of $70.00, for a total value of $63,000.00. Following the sale, the director now directly owns 900 shares in the company, valued at approximately $63,000. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Shares of Prothena Corporation PLC (NASDAQ:PRTA) opened at 64.77 on Monday. Prothena Corporation PLC has a one year low of $40.58 and a one year high of $70.00. The stock has a 50 day moving average price of $59.56 and a 200 day moving average price of $56.28. The firm’s market cap is $2.48 billion.

Prothena Corporation PLC (NASDAQ:PRTA) last issued its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.46) EPS for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.43. The firm had revenue of $26.81 million for the quarter, compared to analyst estimates of $16.08 million. Prothena Corporation PLC had a negative net margin of 527.56% and a negative return on equity of 33.20%. The company’s revenue was up 7951.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($1.18) EPS. On average, equities research analysts forecast that Prothena Corporation PLC will post ($4.39) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This piece of content was first published by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece of content can be accessed at https://www.watchlistnews.com/prothena-corporation-plc-prta-director-sells-63000-00-in-stock/1602688.html.

PRTA has been the subject of a number of analyst reports. Royal Bank Of Canada reiterated a “buy” rating on shares of Prothena Corporation PLC in a research report on Friday. BTIG Research lowered their price target on Prothena Corporation PLC from $80.00 to $77.00 and set a “buy” rating on the stock in a report on Friday. Cantor Fitzgerald reissued a “buy” rating and set a $79.00 price target on shares of Prothena Corporation PLC in a report on Thursday. ValuEngine upgraded shares of Prothena Corporation PLC from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Finally, Evercore ISI assumed coverage on shares of Prothena Corporation PLC in a research note on Wednesday, August 16th. They set an “outperform” rating and a $83.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $78.58.

Hedge funds have recently made changes to their positions in the company. Russell Investments Group Ltd. grew its stake in shares of Prothena Corporation PLC by 12.8% during the first quarter. Russell Investments Group Ltd. now owns 12,030 shares of the biotechnology company’s stock valued at $671,000 after purchasing an additional 1,369 shares during the last quarter. Bank of New York Mellon Corp increased its holdings in shares of Prothena Corporation PLC by 6.4% in the first quarter. Bank of New York Mellon Corp now owns 171,970 shares of the biotechnology company’s stock valued at $9,594,000 after purchasing an additional 10,397 shares in the last quarter. Swiss National Bank increased its holdings in shares of Prothena Corporation PLC by 31.2% in the first quarter. Swiss National Bank now owns 62,300 shares of the biotechnology company’s stock valued at $3,476,000 after purchasing an additional 14,800 shares in the last quarter. Karp Capital Management Corp acquired a new stake in shares of Prothena Corporation PLC in the first quarter valued at approximately $243,000. Finally, Ameritas Investment Partners Inc. acquired a new stake in shares of Prothena Corporation PLC in the first quarter valued at approximately $167,000.

About Prothena Corporation PLC

Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).

Insider Buying and Selling by Quarter for Prothena Corporation PLC (NASDAQ:PRTA)

Receive News & Ratings for Prothena Corporation PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena Corporation PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.